Edaravone improves the expression of nerve growth factor in human astrocytes subjected to hypoxia/reoxygenation

Edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-one), a free radical scavenger, is known to ameliorate postischemic neuronal dysfunction. Nerve growth factor (NGF) is essential for neuronal growth and survival We have addressed the effect of edaravone on the NGF expression in astrocytes exposed to hypoxia/reoxygenation. Normal human astrocytes in culture were incubated under hypoxia for 3 h and then treated with edaravone tinder normal culture condition for up to 72 h The levels of NGF mRNA were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) or real-time quantitative PCR and NGF protein levels were measured by enzyme-linked immunosorbent assay (ELISA). Edaravone enhanced, in time- and concentration-dependent manners, the expressions of NGF mRNA and protein in astrocytes tinder reoxygenation condition. After the treatment for 72 h, 1 mmol/L edaravone enhanced the levels of NGF protein in astrocyte-conditioned media by 1.7-fold of the control An inhibitor of c-Jun N-terminal kinase (JNK) suppressed the effect of edaravone on the NGF expression, and cellular levels of phospho-JNK were increased in response to edaravone We conclude that edaravone enhances, via the JNK pathway, NGF expression in astrocytes This agent may exert a neurotrophic effect in the therapy of brain injury in ischemia/reperfusion. (C) 2009 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.